DUBLIN, Ireland--(BUSINESS WIRE)--May 26, 2006 Elan Corporation, plc today announced the appointment of Mr. William R. Rohn to the company's Board of Directors. Elan's chairman, Kyran McLaughlin, said, "The Board is extremely pleased to announce the appointment of Bill. His extensive experience in the pharmaceutical and biotech industries, together with his personal qualities, will make him an excellent addition to the Board and we all look forward to working with him". Kelly Martin, Elan's president and chief executive officer, added: "I look forward to working with Bill and benefiting from the experience he brings with him". Mr. Rohn (62) is an experienced biotech and pharmaceutical industry executive. He is currently Vice Chairman of Raven Biotechnologies, Inc., and a Director of Metabasis Therapeutics, Inc., Cerus Corp and Pharmacyclics, Inc. Previously he was Chief Operating Officer of Biogen Idec until January 2005 and prior thereto President and Chief Operating Officer of Idec Pharmaceutical Corporation from 1993. About Elan Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com. CONTACT: Elan Corporation, plc Investor Relations: Emer Reynolds, 353-1-709-4000 or Chris Burns, 800-252-3526 or Media Relations: Davia Temin, 212-407-5740 or Elizabeth Headon, 353-1-498-0300
Elan Announces the Appointment of a New Board Director
Press spacebar to pause and continue. Press esc to stop.